Pricing Log in Create free account

Avalo Therapeutics, Inc. (AVTX) vs Gyre Therapeutics, Inc. (GYRE)

Avalo Therapeutics, Inc. and Gyre Therapeutics, Inc. are both Biotechnology companies. Avalo Therapeutics, Inc. and Gyre Therapeutics, Inc. are of similar size ($678.6M and $644.1M). Gyre Therapeutics, Inc. grew revenue faster over the last twelve months: 10.7% against −92.7%. Avalo Therapeutics, Inc. has the higher net margin (0.00% vs −13.7%) and the lower return on invested capital (−118.2% vs −8.51%). Across the 17 metrics below, Gyre Therapeutics, Inc. leads on 11 and Avalo Therapeutics, Inc. on 6.

Valuation

Metric AVTX GYRE Biotechnology median
P/E n/m n/m 8.50
P/S 394.06 5.26 9.71
P/B 1.10 4.29 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 82.27 4.66 9.21
Earnings yield (38.78%) (3.29%) (33.15%)
Free cash flow yield (28.32%) (1.16%) (25.50%)

Profitability

Metric AVTX GYRE Biotechnology median
Gross margin 64.72% 94.15% 65.16%
Operating margin 0.00% (10.53%) 0.00%
Net margin 0.00% (13.73%) 0.00%
Free cash flow margin 0.00% (6.12%) 0.00%
Return on equity (36.27%) (11.75%) (56.36%)
Return on assets (32.50%) (9.08%) (48.04%)
Return on invested capital (118.21%) (8.51%) 0.00%

Growth

Metric AVTX GYRE Biotechnology median
Revenue growth (TTM) (92.65%) 10.72% 6.02%
EPS growth (last fiscal year) (24.62%) (60.00%) 30.26%
Revenue growth, 5-year CAGR (61.19%) 40.96% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AVTX GYRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 19.31 4.26 4.72
Net debt to EBITDA 1.36 (3.74) 0.96

Dividend

Metric AVTX GYRE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AVTX GYRE Biotechnology median
Market cap 644.10m 678.62m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack